ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
21.042,00
0,18%
S&P 500
6.049,24
0,88%
Dow Jones
44.025,81
1,24%
Euro vs US Dollar
1,04131
0,07%
Bitcoin
106.010,33
-0,16%
Pepperstone
Advertisement
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ

  6. Achilles Therapeutics PLC (ACHL) Börsenkurse

Achilles Therapeutics PLC

Achilles Therapeutics PLC (ACHL)

NASDAQ
1,15
0,01
(0,88%)
Geschlossen 22 Januar 10:00PM
Verzögert um 15 Minuten
1,16
0,01
(0,87%)
Nach Börsenschluss: 11:37PM
Verzögert um 15 Minuten

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Wichtige Statistiken und Details

Current Price
1,16
Gebot
1,07
Fragen
1,16
Volumen
75.046
1,1206 Tagesbereich 1,16
0,00 52-Wochen-Bereich 0,00
Marktkapitalisierung
47,656M
Handelsende
1,14
Handelsbeginn
1,13
Letzte Trade
15
@
1.16
Letzter Handelszeitpunkt
Finanzvolumen
US$ 85.428
VWAP
1,1383
Durchschnittliches Volumen (3 Mio.)
-
Ausgegebene Aktien
41.082.948
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
0,00
Gewinn pro Aktie (EPS)
-
Erlöse
6,08M
Nettogewinn
-69,67M

Über Achilles Therapeutics PLC

Achilles Therapeutics PLC is a biopharmaceutical company. It is developing novel cancer immunotherapies targeting clonal neoantigens. The company has two ongoing trials, the CHIRON trial in patients with advanced non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastati... Achilles Therapeutics PLC is a biopharmaceutical company. It is developing novel cancer immunotherapies targeting clonal neoantigens. The company has two ongoing trials, the CHIRON trial in patients with advanced non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma. Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Website
www.achillestx.com
Hauptsitz
London, Gbr
Gegründet
-
Achilles Therapeutics PLC is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ACHL. The last closing price for Achilles Therapeutics was US$1,14. Over the last year, Achilles Therapeutics shares have traded in a share price range of US$ 0,00 to US$ 0,00.

Achilles Therapeutics currently has 41.082.948 shares in issue. The market capitalisation of Achilles Therapeutics is US$46,83 million.

ACHL Neueste Nachrichten

Weitere Nachrichten

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

06 Januar 2025
Edgar (US Regulatory)

Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca

- Proprietary data and samples from TRACERx and Achilles’ Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction - - Conclusion of Strategic Review - LONDON...

24 Dezember 2024
GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

02 Dezember 2024
Edgar (US Regulatory)

Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market

LONDON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced that on November 15, 2024, the Listing Qualifications department of the Nasdaq Stock Market...

19 November 2024
GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

14 November 2024
Edgar (US Regulatory)

Achilles Therapeutics Reports Third Quarter 2024 Financial Results

– Cash position of $86.1 million as of September 30, 2024, not including cash R&D tax credit of $12.8 million received in October 2024 –         LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE...

14 November 2024
GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

19 September 2024
Edgar (US Regulatory)

Achilles Therapeutics Announces Strategic Update

–Achilles to discontinue development of TIL-based cNeT therapy– –Cash position of $95.1 million as of June 30, 2024– –BofA Securities engaged to provide strategic financial advice–        ...

19 September 2024
GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

14 August 2024
Edgar (US Regulatory)

Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates

– Announced research collaboration with Arcturus Therapeutics to explore second-generation mRNA cancer vaccines using Achilles’ AI-powered, tumor-targeting technology – – Provided interim Phase...

14 August 2024
GlobeNewswire Inc.
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

ACHL - Frequently Asked Questions (FAQ)

What is the current Achilles Therapeutics share price?
The current share price of Achilles Therapeutics is US$ 1,16
How many Achilles Therapeutics shares are in issue?
Achilles Therapeutics has 41.082.948 shares in issue
What is the market cap of Achilles Therapeutics?
The market capitalisation of Achilles Therapeutics is USD 46,83M
What is the 1 year trading range for Achilles Therapeutics share price?
Achilles Therapeutics has traded in the range of US$ 0,00 to US$ 0,00 during the past year
What is the reporting currency for Achilles Therapeutics?
Achilles Therapeutics reports financial results in USD
What is the latest annual turnover for Achilles Therapeutics?
The latest annual turnover of Achilles Therapeutics is USD 6,08M
What is the latest annual profit for Achilles Therapeutics?
The latest annual profit of Achilles Therapeutics is USD -69,67M
What is the registered address of Achilles Therapeutics?
The registered address for Achilles Therapeutics is 245 HAMMERSMITH ROAD, LONDON, W6 8PW
What is the Achilles Therapeutics website address?
The website address for Achilles Therapeutics is www.achillestx.com
Which industry sector does Achilles Therapeutics operate in?
Achilles Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
ASSTAsset Entities Inc
US$ 0,8998
(93,71%)
262,98M
DWTXDogwood Therapeutics Inc
US$ 3,18
(70,05%)
24,28M
USEGUS Energy Corp
US$ 3,74
(61,21%)
107,77M
DOGZDogness International Corporation
US$ 27,62
(52,60%)
1,93M
MYNAMynaric AG
US$ 0,6697
(50,83%)
3,72M
GOEVCanoo Inc
US$ 0,3748
(-72,24%)
41,38M
SHOTWSafety Shot Inc
US$ 0,1094
(-47,40%)
18,06k
ORKTOrangeKloud Technology Inc
US$ 0,7068
(-36,89%)
7,48M
HEPAHepion Pharmaceuticals Inc
US$ 0,3219
(-31,36%)
1,66M
WNWMeiwu Technology Company Ltd
US$ 0,2681
(-27,05%)
11,02M
GCTKGlucoTrack Inc
US$ 0,1226
(44,41%)
614,77M
CRKNCrown Electrokinetics Corporation
US$ 0,1121
(-10,32%)
393,29M
ASSTAsset Entities Inc
US$ 0,8998
(93,71%)
263,47M
RIMEAlgorhythm Holdings Inc
US$ 0,034599
(-16,83%)
230,94M
RGTIRigetti Computing Inc
US$ 13,97
(42,12%)
226,96M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

NASDAQ
ACHL
Achilles Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten